JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.41, sa.12, ss.1380-1387, 2011 (SCI-Expanded)
Objective: Therapy targeted against the vascular endothelial growth factor pathway is a standard of care for patients with metastatic renal cell carcinoma. This study assessed the response rates and toxicity profiles of sunitinib on a continuous once-daily dosing regimen in Turkish patients with metastatic renal cell carcinoma.